These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11998504)

  • 1. Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
    Moul JW; Civitelli K
    Urol Nurs; 2001 Dec; 21(6):385-8, 393-4; quiz 395-6. PubMed ID: 11998504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
    Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
    [No Abstract]   [Full Text] [Related]  

  • 3. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer.
    Fowler JE;
    Urology; 2001 Sep; 58(3):430-4. PubMed ID: 11549494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.
    Fowler JE; Flanagan M; Gleason DM; Klimberg IW; Gottesman JE; Sharifi R
    Urology; 2000 May; 55(5):639-42. PubMed ID: 10792069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leuprorelin acetate in prostate cancer: a European update.
    Persad R
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.
    Fowler JE; Gottesman JE; Reid CF; Andriole GL; Soloway MS
    J Urol; 2000 Sep; 164(3 Pt 1):730-4. PubMed ID: 10953135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
    Yri OE; Bjoro T; Fossa SD
    Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
    Marks LS
    Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leuprorelin implant (ALZA). DUROS, leuprolide acetate implant, leuprolide implant, Viadur.
    Drugs R D; 1999 Dec; 2(6):425-6. PubMed ID: 10763458
    [No Abstract]   [Full Text] [Related]  

  • 17. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 20. Implantable LHRH agonist for treatment of prostate cancer.
    Lajiness MJ
    Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.